These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9988833)

  • 21. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
    Schwingl PJ; Shelton J
    Contraception; 1997 Mar; 55(3):125-9. PubMed ID: 9114999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.
    Jick H; Kaye JA; Vasilakis-Scaramozza C; Jick SS
    BMJ; 2000 Nov; 321(7270):1190-5. PubMed ID: 11073511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral contraception and venous thromboembolism. A New Zealand perspective.
    Roke C
    Drug Saf; 1997 Feb; 16(2):79-87. PubMed ID: 9067120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venous thromboembolism among new users of different oral contraceptives.
    Herings RM; Urquhart J; Leufkens HG
    Lancet; 1999 Jul; 354(9173):127-8. PubMed ID: 10408492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral contraceptives, thrombosis and haemostasis.
    Rosing J; Curvers J; Tans G
    Eur J Obstet Gynecol Reprod Biol; 2001 Apr; 95(2):193-7. PubMed ID: 11301170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.
    Kemmeren JM; Algra A; Grobbee DE
    BMJ; 2001 Jul; 323(7305):131-4. PubMed ID: 11463678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third-generation oral contraceptives: how risky?
    Weiss N
    Lancet; 1995 Dec; 346(8990):1570. PubMed ID: 7500743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
    Plu-Bureau G; Sabbagh E; Hugon-Rodin J
    Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database.
    Todd J; Lawrenson R; Farmer RD; Williams TJ; Leydon GM
    Hum Reprod; 1999 Jun; 14(6):1500-5. PubMed ID: 10357966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis.
    Hennessy S; Berlin JA; Kinman JL; Margolis DJ; Marcus SM; Strom BL
    Contraception; 2001 Aug; 64(2):125-33. PubMed ID: 11704089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral contraceptives and venous thromboembolism: an epidemiological review.
    Lidegaard O
    Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in prescription patterns of oral contraceptives in a northern Italian province: relation with venous thromboembolism.
    Girolami A; Spiezia L; Vianello F; Girolami B; Fabris F
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):125-30. PubMed ID: 12812381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Department of health changes advice on third generation pills.
    Mayor S
    BMJ; 1999 Apr; 318(7190):1026. PubMed ID: 10205088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined oral contraceptives: venous thrombosis.
    de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
    Lidegaard Ø; Nielsen LH; Skovlund CW; Skjeldestad FE; Løkkegaard E
    BMJ; 2011 Oct; 343():d6423. PubMed ID: 22027398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Third generation oral contraceptives.
    Skegg DC
    BMJ; 2000 Jul; 321(7255):190-1. PubMed ID: 10903631
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.